There are 2867 resources available
1734MO - Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials
Presenter: Tim Smith
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA54 - Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial
Presenter: Mustafa Ozguroglu
Session: Proffered Paper session: NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century
Resources:
Webcast
Discussion
Presenter: All Speakers
Session: Targeting DNA repair and beyond in ovarian cancer
Resources:
Slides
Webcast
Invited Discussant LBA75, 1733MO and 1734MO
Presenter: Joaquim Bellmunt
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
Conclusions
Presenter: Ron Mathijssen
Session: Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice
Resources:
Slides
Webcast
Metastatic non-small-cell lung cancer: Clinical case
Presenter: Laura Mezquita
Session: ESMO Clinical Practice Guidelines session 2
Resources:
Slides
Webcast
1663MO - DAV132 prevents antibiotic-induced intestinal microbiota dysbiosis and maintains anti-PD-1 efficacy: A proof-of-concept in tumor-bearing mice transplanted with human feces
Presenter: Meriem Messaoudene
Session: Mini Oral session: Basic science & translational research
Resources:
Abstract
Slides
Webcast
972O - Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial
Presenter: Gerard Zalcman
Session: Proffered Paper session: NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA12 - Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
Presenter: Antoine Hollebecque
Session: Proffered Paper session 2: GI, upper digestive
Resources:
Abstract
Slides
Webcast